AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 231 min read$ABBV

AbbVie Receives FDA Approval for Skyrizi Subcutaneous Induction Regimen to Treat Crohn's Disease

AbbVie received FDA approval for a subcutaneous induction regimen of Skyrizi to treat Crohn's disease. The company's stock closed at $285.64, up 0.16%.

Original reporting
marketscreener.com
Published Oct 23, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The approval adds a new indication, potentially increasing sales and improving AbbVie's growth outlook, which may drive the stock higher.

02

Market read

A fresh FDA approval is a material catalyst for AbbVie, offering traders a timely opportunity to act on expected stock appreciation.

03

What to watch

Potential reimbursement challenges and competition from other Crohn's therapies could limit upside.

Relevance 7/10Novelty 9/10Timing: post‑market today

Background

AbbVie announced FDA approval for a new subcutaneous induction regimen of its drug Skyrizi, expanding its Crohn's disease treatment portfolio.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie received FDA approval for a new subcutaneous induction regimen of Skyrizi to treat Crohn's disease.

Expected impact

likely upward pressure as the market prices in the new indication approval

Evidence & confidence

FDA clearance adds a new revenue stream and expands the drug's market, which traders typically reward with price gains.

Market effects

Sector

Biotech and pharma sector may see a modest rally as the approval highlights pipeline potential.

Regional

U.S. healthcare stocks could benefit, with limited immediate effect on other regions.

Global

Global investors tracking FDA decisions will note the approval, but impact remains concentrated on AbbVie.

Counterpoint

What could challenge this read

If the market has already priced in the approval, the stock may face a short‑term sell‑off on profit taking.

Key entities

  • company
    AbbVie

    U.S. biopharma company receiving FDA approval.

  • regulatory_body
    FDA

    U.S. Food and Drug Administration granting the approval.

Read at source← All news

StoryFDA approves subcutaneous induction regimen of AbbVie’s SKYRIZI for Crohn’s disease

Also covered by

5 outlets

Related articles

OCT 23
$ABBVHigh

Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval follows positive Phase 3 trial results, showing significant clinical remission and endoscopic response in patients. SKYRIZI can now be administered at home using an on-body injector, with induction doses at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks.

marketscreener.com2 min
OCT 23
$ABBVHigh

AbbVie (ABBV) Gains FDA Nod for At-Home Skyrizi Induction in Cro

AbbVie (ABBV) received FDA approval for an at-home subcutaneous induction regimen for its drug Skyrizi, allowing adults with moderate to severe Crohn’s disease to start treatment at home. The company offers a 2.34% dividend yield with a high payout ratio of 85% and a 3-year dividend growth rate of 5.2%. AbbVie's GF Value™ suggests the stock is modestly overvalued at $222.72 versus the current price of $286.20.

gurufocus.com3 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min
OCT 23
$ABBVHigh

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

AbbVie (ABBV) received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease. The regimen involves 720 mg doses at weeks 0, 2, 4, and 8, with maintenance doses every 8 weeks. The approval is based on Phase 3 trial results showing 56% clinical remission vs. 30% for placebo. The FDA also updated prescribing info to remove mandatory TB testing. Skyrizi is approved for several autoimmune diseases.

investing.com2 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI® (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on Phase 3 AFFIRM trial results showing superior clinical remission and endoscopic response at week 12 compared to placebo, with no new safety risks identified. The subcutaneous option allows for at-home treatment using an on-body injector.

news.abbvie.com3 min